Disclosures for "Modelling the Impact of Improved Diagnosis and Treatment With Silencers on Disease Progression in Hereditary Transthyretin Amyloidosis With Polyneuropathy (ATTRv-PN)"
-
Dr. Halabi has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for AstraZeneca. Dr. Halabi has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Ionis. Dr. Halabi has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion. Dr. Halabi has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for PeerVoice. Dr. Halabi has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Astellas/Pfizer. Dr. Halabi has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for ADVI. Dr. Halabi has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alnylam. Dr. Halabi has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for AstraZeneca. Dr. Halabi has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Intellia Therapeutics. The institution of Dr. Halabi has received research support from Pharnext. The institution of Dr. Halabi has received research support from AstraZeneca.
-
Mrs. Chen has received personal compensation for serving as an employee of AstraZeneca. Mrs. Chen has stock in AstraZeneca.
-
Dr. Coker has nothing to disclose.
-
Mr. Goldspink has nothing to disclose.
-
Ms. Ko has nothing to disclose.
-
Dr. Papas has received personal compensation for serving as an employee of AstraZeneca. Dr. Papas has stock in AstraZeneca.
-
Susan Grandy has received personal compensation for serving as an employee of ASTRAZENECA. Susan Grandy has stock in ASTRAZENECA.